Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial


Por: Rades D, Conde-Moreno AJ, Cacicedo J, Šegedin B, Stanic K, Metz M, Rudat V, Schild SE

Publicada: 1 feb 2018
Resumen:
Background/Aim: According to our randomized trial, 5x4Gy was comparable to 10x3Gy for metastatic spinal cord compression. Since it remained unclear whether findings applied to poor and intermediate prognoses patients, subgroup analyses were performed. Patients and Methods: In patients with poor prognoses, 58 received 5x4Gy, 53 received 10x3Gy. In intermediate-prognoses patients, numbers were 43 and 49. Results: In patients with poor prognoses, 1-month overall response (OR) was 85% after 5x4Gy and 10x3Gy (p=0.99), improvement 38% vs. 42%, ambulatory status 60% vs. 64% (p=0.83), 6-month local progression-free survival (LPFS) 75% vs. 69% (p=0.74) and 6-month overall survival (OS) 26% vs. 19% (p=0.43). In patients with intermediate prognoses, 1-month OR was 89% after 5x4Gy and 93% after 10x3Gy (p=0.85), improvement 39% vs. 45%, ambulatory status 84% vs. 82% (p=0.90), 6-month LPFS 79% vs. 92% (p=0.17) and 6-months OS 65% vs. 58% (p=0.65). Conclusion: 5x4Gy was not significantly inferior to 10x3Gy in both subgroups.

Filiaciones:
Rades D:
 Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

Conde-Moreno AJ:
 Department of Radiation Oncology, Consorcio Hospital Provincial de Castellón, Castellón, Spain

Cacicedo J:
 Department of Radiation Oncology, Cruces University Hospital, Barakaldo, Spain

Šegedin B:
 Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Stanic K:
 Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Metz M:
 Department of Radiation Oncology, University of Würzburg, Würzburg, Germany

Rudat V:
 Department of Radiation Oncology, Saad Specialist Hospital, Al-Khobar, Kingdom of Saudi Arabia

Schild SE:
 Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A
ISSN: 02507005





Anticancer Research
Editorial
INT INST ANTICANCER RESEARCH, EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE, Grecia
Tipo de documento: Article
Volumen: 38 Número: 2
Páginas: 1009-1015
WOS Id: 000423315300054
ID de PubMed: 29374734

MÉTRICAS